Skip to content
Companies

Akelos

Non-opioid drugs for neuropathic pain

Raised to date

$1.5M

across 1 Form D filing

Investors
81
Last filed
Mar 16, 2026

About

Akelos, Inc. is a clinical-stage biopharmaceutical company founded in 2018, focused on the development of novel, non-opioid therapeutics for neuropathic pain. The company is advancing first-in-class compounds that utilize a unique mechanism of action to address a significant unmet medical need in a large patient population.

The company's key differentiator is its development of non-addictive, non-narcotic drugs that selectively inhibit the HCN1 channel. This novel approach aims to provide effective pain relief without the common side effects associated with existing treatments, such as opioids or SNRIs.

Funding

  • EquityFiled Mar 16, 2026Form D
    $1.5M/ no target

Product

AKE-1018

Neuropathic Pain Therapeutic

AKE-1018 is the company's primary lead drug candidate, an anti-hyperalgesic compound currently in preclinical development. It is designed to treat neuropathic pain by selectively inhibiting the activity of the HCN1 ion channel, representing a new approach to pain management.

  • Selectively inhibits HCN1 channel activity
  • Non-opioid and non-narcotic formulation
  • Designed to avoid common side effects like nausea, lethargy, and constipation

Built for

The primary target segment is the global population of patients diagnosed with neuropathic pain.

People on file